# A Rare Presentation of Five Primary Cancers in a Patient With Werner Syndrome: A Case Report and Literature Review

## TL;DR

A rare case of a Werner syndrome patient living past 80 with five different cancers is reported, highlighting unusual tumor types and the need for tailored treatments.

## Contribution

This case report uniquely documents five primary cancers in a Werner syndrome patient with an atypically long lifespan.

## Key findings

- The patient developed five distinct primary cancers over ten years, including BCC, urothelial carcinoma, TNBC, colonic adenocarcinoma, and IPMN.
- The patient's survival beyond the typical life expectancy of WS suggests potential mechanisms for extended lifespan and atypical tumor development.
- The case emphasizes the need for further research into tailored therapeutic strategies for WS patients.

## Abstract

Werner syndrome (WS) is a rare autosomal recessive disorder characterized by premature aging and a higher cancer risk. WS patients are characterized by a defective gene product, WRN, that plays an instrumental role in the genomic stability of DNA structures. It typically manifests in late adolescence or early adulthood, leading to premature aging, age-related disorders like diabetes, and myocardial infarction, and an increased propensity for developing sarcomas, melanoma, and solid tissue cancer. We present a rare case of an 80-year-old female with WS developing five different primary cancers over a decade namely basal cell carcinoma (BCC) of the face, left-sided urothelial carcinoma, right-sided triple-negative breast cancer (TNBC), right-sided invasive colonic adenocarcinoma, and pancreatic intraductal papillary mucinous neoplasm (IPMN). Our case report is unique in presentation it defies the expected life expectancy of the 50s seen in WS, with the patient currently exhibiting a stable clinical course. This case highlights the need for further research into the mechanisms behind extended lifespan and atypical tumor spectra in such patients, as well as the development of tailored therapeutic strategies, particularly with regard to chemotherapy.